ŞPŞakir Pekgöz

Şakir Pekgöz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Şakir Pekgöz has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Oleuropein modulates apoptotic and endothelial-associated markers in a radiation-induced acute renal injury model in rats

    by Serkan Ceylan, Şakir Pekgoz, Yağmur Kara, Zafer Usta, Sinem Gultekın, Yılmaz Akgül, Meltem Çelik

    1. Radiation therapy remains a cornerstone in the treatment of various malignancies; however, radiation-induced renal injury (RIN) is a progressive condition characterized by oxidative stress, infl...

  • Open Access

    L-carnitine protects against methotrexate-induced hepatotoxicity via regulation of apoptosis and metabolic pathways

    by Sakir Pekgoz, Zafer Usta, Yagmur Kara, Ozlem Ozmen

    Methotrexate (MTX) is a widely used chemotherapeutic and immunosuppressive drug; however, its clinical application is limited by dose-dependent hepatotoxicity mediated by oxidative stress, mitochondrial dysfunction, and apoptosis. This study aimed to investigate the potential hepatoprotective effects of L-carnitine (LCR), a mitochondrial cofactor with antioxidant and anti-apoptotic properties, in a rat model of MTX-induced hepatotoxicity. Twenty-four male Wistar rats were randomly divided into four groups: Control, MTX (20 mg/kg, i.p., single dose), LCR (100 mg/kg/day, oral) and MTX + LCR. After 10 days, liver tissues were examined histopathologically, immunohistochemically for CD38 and GLUT1, and by qPCR for BAX and BCL2 expression. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were also measured. MTX administration induced histological injury, upregulated CD38 and GLUT1 expression and altered apoptosis-related genes (BAX↑, BCL2↓) with a trend toward elevated ALT and AST levels. LCR co-treatment improved hepatic histoarchitecture, reduced CD38 and GLUT1 expression and partially normalized BAX/BCL2 expression, with a tendency to restore serum enzyme activity. L-carnitine may attenuate MTX-induced hepatotoxicity by modulating oxidative stress, metabolic stress and apoptotic signaling. These findings suggest a potential role for L-carnitine as an adjuvant to improve hepatic safety during MTX therapy.


  • Agomelatine Alleviates Methotrexate‐Induced Lung Injury by Concurrently Inhibiting CD45/CD68‐Positive Immune Cell Infiltration and Modulating the BAX/BCL2 Apoptosis Pathway

    by Zafer Usta, Şakir Pekgöz, Melda Şahin, Yağmur Kara, Özlem Özmen

    Methotrexate (MTX)‐induced pulmonary toxicity severely limits its clinical use and effective preventive strategies are lacking. This study evaluated the protective effects of agomelatine (AGO), a melatonergic antidepressant, against MTX‐induced lung injury, focusing on its dual‐pathway action targeting both immune cell infiltration and apoptotic signaling. Thirty‐two female Wistar rats were assigned to: Control, AGO (20 mg/kg/day, p.o., 7 days), MTX (single i.p. dose, 20 mg/kg), and MTX + AGO groups. Lung tissues were examined by histopathology, immunohistochemistry (CD45 + , CD68 + ), and RT‐qPCR (BAX, BCL2). MTX administration caused marked pulmonary damage (histopathological score: 2.75 ± 0.25, p < 0.001), significant infiltration of CD45 + leukocytes and CD68 + macrophages and an elevated BAX/BCL2 ratio (3.5 ± 0.4 vs. 1.0 ± 0.2 in Control, p < 0.001). AGO cotreatment significantly ameliorated these alterations via its dual activity, lowering the histopathological score (1.25 ± 0.25, p < 0.01), reducing CD45 + /CD68 immunopositivity, and restoring the BAX/BCL2 ratio toward cell survival (1.4 ± 0.3, p < 0.01 vs. MTX). These findings provide integrated immunohistochemical and molecular evidence supporting the concurrent modulation of immune cell infiltration and apoptotic signaling by AGO in MTX‐induced lung injury. Given its established clinical use and favorable safety profile, AGO may represent a potential adjunctive candidate to reduce the risk of MTX‐related pulmonary complications, through concurrent targeting of immune and apoptotic pathways.


  • Potential Hepatoprotective Effects of Irbesartan, an Accessible Angiotensin II Receptor Blocker, Against Cisplatin-Induced Liver Injury in a Rat Model

    by Onur Ertunç, Yalçın Erzurumlu, Mehtap Savran, Deniz Çatakli, Eltaf Doğan Kiran, Şakir Pekgöz

    Drug-induced liver injury is a common adverse reaction that frequently occurs with chemotherapeutic agents, such as cisplatin (CIS). This study seeks to enhance our understanding of drug actions and their associated adverse effects by examining the toxicity of CIS on rat liver tissue. We aimed to investigate the potential hepatoprotective effects of irbesartan (IRB), an easily accessible angiotensin II receptor blocker, in mitigating CIS-induced hepatotoxicity. Wistar albino rats were divided into four groups. These groups included a control group [saline, per oral (p.o.)] for seven days, and 1 mL saline intraperitoneal [(i.p.) on the fourth day]; a CIS group (1 mL saline for seven days and 7.5 mg/kg CIS i.p. on the fourth day); a CIS + IRB group (IRB: 50 mg/kg p.o. for seven days and 7.5 mg/kg CIS i.p. on the fourth day), and an IRB group (50 mg/kg IRB p.o. for seven days). The effect of IRB on interleukin-1 beta (IL-1β) and caspase 3 levels was evaluated by immunohistochemical analysis, and its effects on mRNA expression levels of CCAAT/enhancer-binding protein homologous protein (CHOP) and immunoglobulin-heavy-chain-binding protein (BiP) were tested by quantitative real-time polymerase chain reaction. IRB administration mitigated CIS-induced liver toxicity by inhibiting endoplasmic reticulum (ER) stress. Specifically, this drug reduced the mRNA expression of ER stress markers, including CHOP and BiP. In addition, IRB treatment decreased oxidative stress, inflammatory responses, and apoptotic markers. These findings suggest that IRB is a promising therapeutic option for preventing CIS-induced liver injury, potentially by modulating ER stress-related pathways.


  • A study on Wistar Albino rats: investigating protective role of ramelteon on liver damage caused by methotrexate

    by Meltem Özgöçmen, Halil Aşcı, Hatice Kübra Doğan, İlTer İlHan, Şakir Pekgöz, Ali Mustafaoğlu

    Methotrexate is an important immunosuppressive and antineoplastic drug and is widely used for treatment. However, hepatotoxicity is one of the major adverse effects of methotrexate. In this study, it was aimed to investigate whether ramelteon has a possible protective effect on hepatotoxicity induced by methotrexate. Thirty-two Wistar albino rats were equally divided into four groups: control, methotrexate, methotrexate + ramelteon, and ramelteon. Following a single dose of 20 mg/kg, methotrexate (i.p.), either saline or ramelteon 10 mg/kg (orally) was administered for 7 days. After treatment, animals were sacrificed, and histopathological analyses were evaluated with Hematoxylin–eosin (H–E), immunohistological analyses were evaluated with Interleukın-1 Beta (IL-1β) and Caspase 3 (CAS-3), biochemical analyzes were evaluated with Total Oxidant Status (TOS), Total antioxidants status (TAS), Oxidative Stress Index (OSI), aspartate aminotransferase (AST), alanine aminotransferase (ALT) activities, at last genetical analyses were evaluated with Sirtuin-1 (SIRT-1) – P53 gene expressions. In the control and ramelteon groups, normal histological structures were observed, while histopathological findings were observed in the methotrexate group. Increasing levels of IL-1β staining, CAS-3 staining, p53 gene expression, TOS, OSI, AST and ALT were observed in methotrexate group while were observed decreasing levels of TAS and SIRT-1 gene expression (p < 0.05). However, ramelteon reduced the increased findings in methotrexate-induced hepatotoxicity (p < 0.05). The results of the present study showed that ramelteon protects against methotrexate induced hepatotoxicity in rats via SIRT-1 signaling by histological, immunohistological, biochemical and genetical analyses.